Literature DB >> 20695034

Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors.

Plinio C Casarotto1, Felipe V Gomes, Leonardo B M Resstel, Francisco S Guimarães.   

Abstract

Cannabidiol (CBD) is a major non-psychotomimetic component of Cannabis sativa that has been shown to have an anxiolytic effect in human and animal models. Earlier studies suggest that these effects involve facilitation of serotonin, a neurotransmitter that has also been related to obsessive-compulsive disorder. On the basis of this evidence, this study investigated the effects of CBD in C57BL/6J mice submitted to the marble-burying test (MBT), an animal model proposed to reflect compulsive behaviour. CBD (15, 30 and 60 mg/kg) induced a significant decrease in the number of buried marbles compared with controls (34, 41 and 48%, respectively). A similar, although larger, decrease was also found after the serotonin selective reuptake inhibitor paroxetine (10 mg/kg, 77% decrease) and the benzodiazepine diazepam (2.5 mg/kg, 84% decrease). The effect of CBD (30 mg/kg) was still significant after 7 days of daily repeated administration, whereas the effect of diazepam disappeared. Pretreatment with WAY100635 (3 mg/kg), a 5HT1A receptor antagonist, prevented the effects of paroxetine but failed to alter those of CBD. These latter effects, however, were prevented by pretreatment with the CB1 receptor antagonist AM251 (1 mg/kg). These results indicated that CBD and paroxetine decrease the number of buried marbles in the MBT through distinct pharmacological mechanisms. They also suggest a potential role of drugs acting on the cannabinoid system in modulating compulsive behaviour.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695034     DOI: 10.1097/fbp.0b013e32833b33c5

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  35 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

2.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

Review 3.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

4.  Methoxetamine affects brain processing involved in emotional response in rats.

Authors:  M T Zanda; P Fadda; S Antinori; M Di Chio; W Fratta; C Chiamulera; L Fattore
Journal:  Br J Pharmacol       Date:  2017-08-19       Impact factor: 8.739

Review 5.  A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: Mapping the way forward.

Authors:  Geoffrey de Brouwer; Arina Fick; Brian H Harvey; De Wet Wolmarans
Journal:  Cogn Affect Behav Neurosci       Date:  2019-02       Impact factor: 3.282

6.  Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Authors:  Sara Jane Ward; Sean D McAllister; Rumi Kawamura; Ryuchi Murase; Harshini Neelakantan; Ellen A Walker
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

7.  Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Authors:  Gustavo Gonzalez-Cuevas; Remi Martin-Fardon; Tony M Kerr; David G Stouffer; Loren H Parsons; Dana C Hammell; Stan L Banks; Audra L Stinchcomb; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2018-03-22       Impact factor: 7.853

8.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Authors:  Serena Deiana; Akihito Watanabe; Yuki Yamasaki; Naoki Amada; Marlene Arthur; Shona Fleming; Hilary Woodcock; Patricia Dorward; Barbara Pigliacampo; Steve Close; Bettina Platt; Gernot Riedel
Journal:  Psychopharmacology (Berl)       Date:  2011-07-28       Impact factor: 4.530

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

10.  Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats.

Authors:  Alline Cristina Campos; Vanessa de Paula Soares; Milene C Carvalho; Frederico Rogerio Ferreira; Maria Adrielle Vicente; Marcus Lira Brandão; Antonio Waldo Zuardi; Hélio Zangrossi; Francisco Silveira Guimarães
Journal:  Psychopharmacology (Berl)       Date:  2012-09-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.